Business Context and Reporting Period
This Form 6-K filing by Bioblast Pharma Ltd. (also referenced as Enlivex Ltd. in metadata) covers the month of September 2017, with a specific report date of September 25, 2017. The filing serves to announce the effectiveness of a five-to-one reverse split of the company's share capital and a corresponding amendment to its articles of association.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a corporate action announcement and does not contain financial performance data.
Material Changes
- Capital Structure: The company executed a five-to-one reverse split of its share capital.
- Corporate Governance: The company's articles of association were amended to reflect the reverse split.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future guidance, outlook, or specific risks. The primary focus is the administrative update regarding the share split. The press release is incorporated by reference into existing registration statements on Form F-3 and Form S-8.
Investor Verification Checklist
- Verify the post-split share count and trading symbol adjustments on the relevant exchange.
- Confirm the updated par value per share following the five-to-one reverse split.
- Review the amended articles of association for any other structural changes beyond the split.
- Check subsequent filings for the impact of the reverse split on outstanding options and warrants.